• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[针对艾滋病病毒的更安全的疫苗和基因疗法试验]

[Safer trials of vaccine and gene therapy against HIV].

作者信息

Ikuta K

机构信息

Section of Serology, Hokkaido University, Sapporo, Japan.

出版信息

Hokkaido Igaku Zasshi. 1996 Jan;71(1):21-6.

PMID:8727371
Abstract

HIV, the etiological agent of AIDS, induces depletion of CD4+T cells. Upon primary infection, there is an initial viremia that is followed rapidly by a cell-mediated immune response and apparent viral clearance. Thereafter, the persistence of low levels of HIV in the blood for years before the onset of the disease is facilitated by the ability of the virus to establish persistent and latent infection. Notwithstanding the latent form in most population, the clinical stage of disease is significantly associated with all measures of virus load levels. This may be mainly due to the function of HIV to induce apoptosis in a patients' uninfected CD4+T cells, as a bystander effect. Thus, the mechanisms that latently infect in the cells after HIV infection and stimulate active replication of HIV from the latency are essential for an understanding of the pathogenicity of the disease. Therefore, prophylactic and therapeutic trials should be focused to their effect to reduce the HIV load level.

摘要

艾滋病的病原体人类免疫缺陷病毒(HIV)会导致CD4+T细胞耗竭。初次感染时,会出现初始病毒血症,随后迅速出现细胞介导的免疫反应以及明显的病毒清除。此后,在疾病发作前的数年里,血液中持续存在低水平的HIV,这得益于该病毒建立持续潜伏感染的能力。尽管在大多数人群中处于潜伏形式,但疾病的临床阶段与病毒载量水平的所有指标均显著相关。这可能主要归因于HIV作为旁观者效应诱导患者未感染的CD4+T细胞凋亡的功能。因此,HIV感染后在细胞中潜伏感染并从潜伏期刺激HIV活跃复制的机制,对于理解该疾病的致病性至关重要。所以,预防和治疗试验应聚焦于它们降低HIV载量水平的效果。

相似文献

1
[Safer trials of vaccine and gene therapy against HIV].[针对艾滋病病毒的更安全的疫苗和基因疗法试验]
Hokkaido Igaku Zasshi. 1996 Jan;71(1):21-6.
2
Molecular biological assessment methods and understanding the course of the HIV infection.分子生物学评估方法与对HIV感染病程的理解
APMIS Suppl. 2003(114):1-37.
3
Human immunodeficiency virus and acquired immunodeficiency syndrome: an update.人类免疫缺陷病毒与获得性免疫缺陷综合征:最新进展
Adv Intern Med. 1994;39:305-55.
4
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.间歇性结构化治疗中断而非用ALVAC-HIV vCP1452进行免疫接种可促进宿主对HIV复制的控制:艾滋病临床试验组5068的结果
J Infect Dis. 2006 Sep 1;194(5):623-32. doi: 10.1086/506364. Epub 2006 Aug 1.
5
Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques.在幼年和新生恒河猴中,含有HIV-1SF33 env基因变异形式的SIV/HIV-1(SHIV)导致的致命免疫发病机制。
Virology. 1999 Oct 10;263(1):112-27. doi: 10.1006/viro.1999.9908.
6
Control of HIV-1 replication in elite suppressors.精英抑制者中HIV-1复制的控制
Discov Med. 2010 Mar;9(46):261-6.
7
Effect of an oral therapeutic HIV-1 vaccine on AIDS patients with CD4 count above 250 cells/mm3.
Acta Virol. 2004;48(2):73-8.
8
Gradual shutdown of virus production resulting in latency is the norm during the chronic phase of human immunodeficiency virus replication and differential rates and mechanisms of shutdown are determined by viral sequences.在人类免疫缺陷病毒复制的慢性阶段,病毒产生逐渐停止并导致潜伏是常态,且停止的不同速率和机制由病毒序列决定。
Virology. 1996 Nov 1;225(1):196-212. doi: 10.1006/viro.1996.0588.
9
In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.用人T细胞白血病病毒I型刺激后,在血浆病毒血症检测不到的个体来源的静息CD4(+) T细胞中体外诱导HIV-1复制
Virology. 2000 Dec 20;278(2):514-9. doi: 10.1006/viro.2000.0684.
10
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
J Infect Dis. 2000 Nov;182(5):1357-64. doi: 10.1086/315860. Epub 2000 Oct 9.